Anatara Lifesciences Unveils Strong Governance & Growth Plans in FY26 Annual Report
Analyze Anatara Lifesciences’ AGM, governance, and FY‑2026 report to reveal solid oversight, a focused non‑antibiotic pipeline, and clear growth prospects for investors.
4 minutes to read